Crossmark

Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient

Crossref DOI link: https://doi.org/10.1007/s12185-025-03994-2

Published Online: 2025-04-29

Published Print: 2025-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oka, Satoko https://orcid.org/0000-0002-5405-9759
Akagi, Yuina

Mituyoshi, Takaya

Ono, Kazuo
License Information

Text and Data Mining valid from 2025-04-29

Version of Record valid from 2025-04-29
More Information

Article History

Received: 6 February 2025

Revised: 9 April 2025

Accepted: 11 April 2025

First Online: 29 April 2025

Declarations

:

: All the authors declare no conflicts of interest.

: The patients provided their written informed consent to receive each regimen, and treatment was administered according to the principles of the Declaration of Helsinki. This study was approved by the Japanese Red Cross Society Wakayama Medical Center ethics committee.

: Informed consent was obtained from all the individual participants included in the study.

: Patient signed informed consent regarding publishing their data and images.

Document is current

Any future updates will be listed below